Cyxone AB (publ) (STO:CYXO)

Market Cap	6.75M
Revenue (ttm)	3.52M
Net Income (ttm)	-22.16M
Shares Out	375.06M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,430,748
Average Volume	2,936,802
Open	0.0220
Previous Close	0.0180
Day's Range	0.0180 - 0.0220
52-Week Range	0.0100 - 0.1610
Beta	0.36
RSI	39.51
Earnings Date	Feb 25, 2025

About Cyxone AB

Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CYXO

Financial Performance

In 2023, Cyxone AB's revenue was 5.15 million, a decrease of -19.55% compared to the previous year's 6.40 million. Losses were -22.99 million, -45.87% less than in 2022.